Acute Myeloid Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Acute Myeloid Leukemia stocks.


Compare ETFs

    Recent Signals

    Date Stock Signal Type
    2021-05-17 HEMO NR7 Range Contraction
    2021-05-17 HEMO NR7-2 Range Contraction
    2021-05-17 HEMO Narrow Range Bar Range Contraction
    2021-05-17 HEMO Boomer Sell Setup Bearish Swing Setup
    2021-05-17 SAR New 52 Week Closing High Bullish
    2021-05-17 SAR New Uptrend Bullish
    2021-05-17 SAR Slingshot Bullish Bullish Swing Setup
    2021-05-17 SAR 20 DMA Support Bullish
    2021-05-17 SAR Expansion Breakout Bullish Swing Setup
    2021-05-17 SAR Expansion Pivot Buy Setup Bullish Swing Setup
    2021-05-17 SAR Pocket Pivot Bullish Swing Setup
    2021-05-17 SAR Reversal New Highs Setup Bullish Swing Setup
    2021-05-17 SAR 50 DMA Support Bullish
    2021-05-17 SAR Volume Surge Other
    2021-05-17 SAR Wide Range Bar Range Expansion

    Recent News for Acute Myeloid Leukemia Stocks

    Date Stock Title
    Related Industries: Drug Manufacturers - Major

    Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cell production. Symptoms may include feeling tired, shortness of breath, easy bruising and bleeding, and increased risk of infection. Occasionally, spread may occur to the brain, skin, or gums. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.Risk factors include smoking, previous chemotherapy or radiation therapy, myelodysplastic syndrome, and exposure to the chemical benzene. The underlying mechanism involves replacement of normal bone marrow with leukemia cells, which results in a drop in red blood cells, platelets, and normal white blood cells. Diagnosis is generally based on bone marrow aspiration and specific blood tests. AML has several subtypes for which treatments and outcomes may vary.AML typically is initially treated with chemotherapy, with the aim of inducing remission. People may then go on to receive additional chemotherapy, radiation therapy, or a stem cell transplant. The specific genetic mutations present within the cancer cells may guide therapy, as well as determine how long that person is likely to survive.In 2015, AML affected about one million people and resulted in 147,000 deaths globally. It most commonly occurs in older adults. Males are affected more often than females. The five-year survival rate is about 35% in people under 60 years old and 10% in people over 60 years old. Older people whose health is too poor for intensive chemotherapy have a typical survival of five to ten months. It accounts for roughly 1.8% of cancer deaths in the United States.

    More about Acute Myeloid Leukemia
    Browse All Tags